Table 3.
Biochemical parameters before and after combined targeted immunosuppressive therapy
| Pretherapy | Posttherapy | P value | |
|---|---|---|---|
| Median (25th, 75th IQR) | Median (25th, 75th IQR) | ||
| Fasting glucose (mg/dL) | 307 (203, 397.8) | 79.5 (75.7, 92) | <0.0001* |
| HbA1c (%) | 11.8 (9.7, 13.6) | 5.5 (5.2, 6) | <0.0001* |
| Insulin dose (units/day) | 1,775 (863, 2,700) | 0 | 0.007* |
| Testosterone (ng/dL) | |||
| Women | 126 (57, 571) | 28 (20, 47) | 0.013* |
| Men | 635 (453.5, 789.5) | 499 (432, 566) | 0.04* |
| Triglycerides (mg/dL) | 58 (42, 73) | 55 (43, 81) | 0.87 |
| Total cholesterol (mg/dL) | 129 (119, 145) | 152 (133, 156) | 0.28 |
| LDL cholesterol (mg/dL) | 59.5 (46, 78) | 72 (56, 91) | 0.17 |
| HDL cholesterol (mg/dL) | 58.5 (55, 73) | 60 (47, 79) | 0.66 |
There was normalization of fasting glycemia, significant reduction of HbA1c, reduction of daily insulin dosage to 0 units/day, and normalization of testosterone levels. There were no significant effects on lipids panel. Reference values for androgens in women: testosterone premenopausal women <81 ng/dL, postmenopausal women <63 ng/dL.
*Statistically significant (P < 0.05).